Imaging Biometrics Ltd. (IBAI.L)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 1 | 1 | 1 | 1 | 1 | 1 | - |
| Operating profit | £m | -0 | - | ||||||
| Net profit | £m | -1 | -1 | -1 | -1 | -0 | -0 | -0 | - |
| EPS reported | £ | -0.00 | -0.00 | ||||||
| Operating cashflow per share | £ | 0.00 | 0.00 | ||||||
| Capex per share | £ | 0.00 | 0.00 | ||||||
| FCF per share | £ | 0.00 | 0.00 | ||||||
| Free cash flow | £m | 0 | 0 | ||||||
| Net debt | £m | 0 | 0 | ||||||
| Book value equity | £m | 0 | 0 | ||||||
| Book value per share | £ | 0.00 | 0.00 | ||||||
| Number of shares | m | 241.5 | 273.17 | ||||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 8.72 | 6.67 | ||||||
| P/S LTM | x | 2.60 | 2.53 | ||||||
| P/FCF LTM | x | 27.61 | 13.36 | ||||||
| EV/EBITDA LTM | x | -32.03 | 17.33 | ||||||
| EV/Sales LTM | x | 2.68 | 2.29 | ||||||
| Earnings Yield LTM | % | -19.53% | -13.75% | ||||||
| FCF Yield | % | +3.62% | +7.48% | ||||||
| Quality | |||||||||
| ROE | % | -170.39% | -87.45% | ||||||
| ROIC | % | -38.55% | +4.37% | ||||||
| Operating margin | % | -19.94% | +2.62% | ||||||
| Gross margin | % | +81.98% | +81.58% | ||||||
| FCF/Sales | % | +9.43% | +18.96% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +5.07% | +8.04% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.43 | 0.87 | ||||||
| Net Debt/EBITDA | x | -0.91 | 1.05 | ||||||
| EBIT/Net interest | x | -67.75 | 2.85 | ||||||
| Net debt/market cap | % | +8.39% | +10.27% | ||||||
| Net debt/Equity | x | 0.25 | 0.42 | ||||||
| Gross debt/equity | x | 0.73 | 0.58 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and the United States. Its operations are structured into three main segments: a Holding Company, Medical Software, and Oral Gallium Maltolate (GaM). The Medical Software division develops a comprehensive suite of ready-to-use software applications for the healthcare sector. This portfolio includes IB Clinic, which serves as the foundational platform for all IB software; IB Neuro, a specialized platform for MR DSC perfusion processing; and IB Delta Suite, designed to generate Delta T1 maps from routine MR examinations. Further offerings comprise IB DCE and IB Diffusion, both providing in-depth insights into blood flow and water diffusion throughout the body. For non-invasive assessments, the company provides StoneChecker and Liver Surface Nodularity, which are computed tomography (CT) processing tools that assist clinicians in evaluating kidney stones and liver health. Additional software includes IB ASL, used to measure cerebral blood flow for diagnosing conditions like stroke and dementia, and IB Zero G, an innovative technology that eliminates the need for gadolinium contrast agents in standard imaging. The suite also features IB Nimble, facilitating virtual collaboration among healthcare professionals. Beyond software, the company's Oral Gallium Maltolate (GaM) segment is actively pursuing the development of IB003, a gallium maltolate drug candidate currently in Phase 1 clinical trials for treating glioblastoma. Imaging Biometrics Ltd. also offers consulting services. The entity, which was previously known as IQ-AI Limited, is slated to adopt the name Imaging Biometrics Ltd. in May 2025.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and the United States. Its operations are structured into three main segments: a Holding Company, Medical Software, and Oral Gallium Maltolate (GaM). The Medical Software division develops a comprehensive suite of ready-to-use software applications for the healthcare sector. This portfolio includes IB Clinic, which serves as the foundational platform for all IB software; IB Neuro, a specialized platform for MR DSC perfusion processing; and IB Delta Suite, designed to generate Delta T1 maps from routine MR examinations. Further offerings comprise IB DCE and IB Diffusion, both providing in-depth insights into blood flow and water diffusion throughout the body. For non-invasive assessments, the company provides StoneChecker and Liver Surface Nodularity, which are computed tomography (CT) processing tools that assist clinicians in evaluating kidney stones and liver health. Additional software includes IB ASL, used to measure cerebral blood flow for diagnosing conditions like stroke and dementia, and IB Zero G, an innovative technology that eliminates the need for gadolinium contrast agents in standard imaging. The suite also features IB Nimble, facilitating virtual collaboration among healthcare professionals. Beyond software, the company's Oral Gallium Maltolate (GaM) segment is actively pursuing the development of IB003, a gallium maltolate drug candidate currently in Phase 1 clinical trials for treating glioblastoma. Imaging Biometrics Ltd. also offers consulting services. The entity, which was previously known as IQ-AI Limited, is slated to adopt the name Imaging Biometrics Ltd. in May 2025.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free